Compare Pfizer Inc (PFE) vs Thomson Reuters Corp (TRI) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Thomson Reuters (TRI) trades at $90.67, down 5.75% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.93% net margin and 12.63% ROE, though recent earnings showed mixed results with a Q4 2025 miss. Recent developments include a joint venture with KKR for the global print business and strategic AI implementation, positioning TRI for future growth in content and technology services.

Wall Street remains optimistic with a $129.96 consensus price target (43% upside), driven by 51.85% buy ratings. Key risks include execution of AI strategy and competitive pressures. The stock offers value with reasonable valuation multiples (P/E 27.47, P/S 5.49) and consistent dividend payments, making it attractive for long-term investors despite near-term volatility.